USA

měiguó

美国

FDA

shíyào

食药

administration

jiānguǎn

监管

bureau

jú

局

approves

pīzhǔn

批准

new

xīnxíng

新型

diabetes

tángniaobìng

糖尿病

drug

yaowu

药物

。

New Words

News in English

FDA Approves Teplizumab to Delay Type 1 Diabetes Progression in Children

The US Food and Drug Administration approved teplizumab on June 12, offering accelerated approval to delay the decline in insulin production in children aged 8 to 17 recently diagnosed with type 1 diabetes.

The US Food and Drug Administration approved teplizumab on June 12, granting accelerated approval to delay the decline in insulin production in children aged 8 to 17 who have recently been diagnosed with stage 3 type 1 diabetes. This marks the first disease-modifying therapy cleared for new-onset stage 3 disease in this age group. Teplizumab is a monoclonal antibody that targets the immune system to slow down the destruction of insulin-producing beta cells in the pancreas. Clinical trials demonstrated that the therapy could significantly delay the progression to insulin dependence in newly diagnosed patients. This approval represents a major breakthrough in type 1 diabetes treatment, offering hope to young patients and their families for slowing disease progression.

More in Lifestyle & Culture